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The goal of FDA’s approach to evaluating nicotine replacement therapies  
should be complete cessation, not “harm reduction,” because the likely result of adopting 
the tobacco industry’s harm reduction frame1,2 will be continued smoking and increases in 
overall harm.  In addition, to ensure that it is effective, FDA should emphasize that use of 
NRT must be accompanied by effective counseling and cessation support, and should 
discourage dual use with other tobacco products. 
 
The essential starting point for FDA’s consideration of the public health, scientific, 
regulatory, and legal considerations relating to nicotine replacement therapy (NRT) products and 
their use in tobacco cessation must be the current scientific evidence showing no level of 
combustible tobacco use is safe. For example, smoking one cigarette a day is sufficient to 
significantly increase the risks for developing stroke and coronary heart disease.3   
 
Smoking reduction should not be the goal or an acceptable outcome of any NRT 
treatment regimen. Rather, complete cigarette cessation and complete abstinence from any 
alternative tobacco products should continue to be the desired endpoint.   
 
Scientific evidence shows that NRT used without counselling is ineffective, or even 
harmful, in terms of promoting cessation.4   The tobacco companies have long understood this 
fact and are now entering the over-the-counter (OTC) NRT business (without providing the 
                                                
1	Peeters	S,	Gilmore	AB.	Understanding	the	emergence	of	the	tobacco	industry's	use	of	the	term	tobacco	harm	
reduction	in	order	to	inform	public	health	policy.	Tob	Control.	2015	Mar;24(2):182-9.	doi:	10.1136/tobaccocontrol-
2013-051502.	Epub	2014	Jan	22.	
2	Peeters	S,	Gilmore	AB.	Transnational	tobacco	company	interests	in	smokeless	tobacco	in	Europe:	analysis	of	
internal	industry	documents	and	contemporary	industry	materials.	PLoS	Med.	2013;10(9):e1001506.	doi:	
10.1371/journal.pmed.1001506.	Epub	2013	Sep	10.	
3	Hackshaw	A,	Morris	JK,	Boniface	S,	Tang	JL,	Milenkovic	D.	Low	cigarette	consumption	and	risk	of	coronary	heart	
disease	and	stroke:	meta-analysis	of	141	cohort	studies	in	55	study	reports.	BMJ.	2018;360:j5855.	Epub	
2018/01/26.	doi:	10.1136/bmj.j5855.	PubMed	PMID:	29367388.	
4		Kotz	D,	Brown	J,	West	R.	Prospective	cohort	study	of	the	effectiveness	of	smoking	cessation	treatments	used	in	
the	“real	world.”	Mayo	Clin	Proc.	2014;89(10):1360–1367.		Kotz	D,	Brown	J,	West	R.	“Real-world”	effectiveness	of	
smoking	cessation	treatments:	a	population	study.	Addiction.	2014;109(3):491–499.		Leas,	EC,	et	al,	Effectiveness	
of	Pharmaceutical	Smoking	Cessation	Aids	in	a	Nationally	Representative	Cohort	of	American	Smokers.		JNCI:	
Journal	of	the	National	Cancer	Institute,	djx240,	https://doi.org/10.1093/jnci/djx240.		Published:	21	December	
2017.	
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needed counselling) as part of their plans to hold on to customers who might otherwise stop 
smoking entirely.5   
 
Given FDA’s mission to protect and promote public health, the most effective and least 
harmful way to provide NRT is to restrict their use to smokers whose quit attempts are medically 
supervised. NRT labeling should include warnings about the potential harms of improperly using 
NRT together with other forms of tobacco products and the risks of using unsupervised NRT 
without monitoring by a health professional or smoking cessation counseling program with the 
end-goal of achieving smoking cessation.  
 
Any efforts to improve OTC NRT effectiveness should include direct efforts to improve 
adherence to NRT, including, but not limited to, public education, making NRT use instructions 
easy to understand for consumers with limited health literacy, and integrating smoking cessation 
counseling support with OTC NRT use.  
 
We elaborate on these points below and respond to specific questions FDA posed in its 
Request for Comments. 
 
1. Might there be ways to improve upon the currently available delivery systems to 
yield new OTC NRT products that might be more effective? If so, what evidence 
would be needed to support such changes, and how should they be evaluated? 
 
Any new OTC NRT product must be evaluated for its abuse liability and potential, 
specifically within the context of how the product(s) may be consumed by users, including 
whether such new products may result in the increased likelihood of concurrent use of cigarettes 
and/or other tobacco products both in the short and long term. Complete cigarette cessation and 
complete abstinence from any alternative tobacco products should be the desired endpoint, 
rather than reduction in consumption of cigarettes and/or other tobacco products given that there 
is little evidence to support health benefits or reduction of harm by continued tobacco use at 
any level.6,7 The FDA needs to be particularly cognizant of the evidence, discussed above, that 
NRT use without smoking cessation counseling or support reduces the likelihood of successful 
smoking cessation, so increases, rather than reduces, harm.  
 
                                                
5	Apollonio	D,	Glantz	SA.		Tobacco	Industry	Research	on	Nicotine	Replacement	Therapy:	"If	Anyone	Is	Going	to	Take	
Away	Our	Business	It	Should	Be	Us".		Am	J	Public	Health.	2017	Oct;107(10):1636-1642.	doi:	
10.2105/AJPH.2017.303935.	Epub	2017	Aug	17. 
6	U.S.	Department	of	Health	and	Human	Services.	The	Health	Consequences	of	Smoking-50	Years	of	Progress:	A	
Report	of	the	Surgeon	General.	Atlanta	(GA):	U.S.	Department	of	Health	and	Human	Services,	Centers	for	Disease	
Control	and	Prevention,	National	Center	for	Chronic	Disease	Prevention	and	Health	Promotion,	Office	on	Smoking	
and	Health,	2014.	
7	Lindson-Hawley	N,	Hartmann-Boyce	J,	Fanshawe	TR,	Begh	R,	Farley	A,	Lancaster	T.	Interventions	to	reduce	harm	
from	continued	tobacco	use.	Cochrane	Database	of	Systematic	Reviews	2016,	Issue	10.	Art.	No.:	CD005231.	DOI:	
10.1002/14651858.CD005231.pub3.	
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While adherence to NRT is a consistent predictor of smoking cessation,8,9 many smokers 
do not use NRT correctly and/or discontinue NRT early.10  Smokers from vulnerable groups 
where smoking prevalence remains high, such as those who are socio-economically 
disadvantaged and those with psychiatric comorbidities, are reportedly more likely to be non-
adherent to NRT.11,12  Qualitative research suggests several factors associated with NRT non-
adherence, including limited health literacy, misunderstanding the purpose of NRT and its 
correct usage, and experience with and fear of side effects.13,14  
 
Non-adherence to NRT can contribute to the limited effectiveness or counter-productive 
effects of NRT observed in real-world settings.  Specifically, evidence shows that NRT used 
without counselling is ineffective or even harmful in terms of promoting cessation.15  
 
Thus, FDA should direct efforts to improve consumers’ adherence to NRT as part of 
the crucial effort devoted to improve OTC NRT effectiveness.  Efforts to increase NRT 
adherence should include, but not be limited to: (1) public education via multiple channels to 
reach all population groups, and specifically those with high smoking prevalence; (2) making 
NRT use instructions easy to understand for consumers with limited health literacy; and (3) 
integrating smoking cessation counseling support with OTC NRT use.  
 
 If these efforts fail, FDA should remove NRT from OTC sale and put it back as a 
prescription drug in an effort to see that its use is properly supervised and monitored. 
 
                                                
8	Okuyemi	KS,	Goldade	K,	Whembolua	GL,	Thomas	JL,	Eischen	S,	Guo	H,	Connett	JE,	Grant	J,	Ahluwalia	JS,	Resnicow	
K,	Owen	G,	Gelberg	L,	Jarlais	DD.	Smoking	characteristics	and	comorbidities	in	the	power	to	quit	randomized	
clinical	trial	for	homeless	smokers.	Nicotine	Tob	Res.	2013	Jan;	15(1):22-8.	
9	Schnoll	RA,	Hitsman	B,	Blazekovic	S,	et	al.	Longitudinal	changes	in	smoking	abstinence	symptoms	and	alternative	
reinforcers	predict	long-term	smoking	cessation	outcomes.	Drug	Alcohol	Depend	2016;165:245-52.	doi:	
10.1016/j.drugalcdep.2016.06.017	
10	Burns	EK,	Levinson	AH.	Discontinuation	of	nicotine	replacement	therapy	among	smoking-cessation	attempters.	
Am	J	Prev	Med	2008;34(3):212-5.	doi:	10.1016/j.amepre.2007.11.010	
11	Handschin	J,	Hitsman	B,	Blazekovic	S,	Veluz-Wilkins	A,	Wileyto	EP,	Leone	FT	et	al.	Factors	Associated	with	
Adherence	to	Transdermal	Nicotine	Patches	within	a	Smoking	Cessation	Effectiveness	Trial.	Journal	of	Smoking	
Cessation.	2017	Mar	9;1-11.	Available	from,	DOI:	10.1017/jsc.2017.2		
12	Ojo-Fati	O,	Thomas	J,	Vogel	R,	Ogedegbe	O,	Jean-Louis	G,	Okuyemi	K.	Predictors	of	Adherence	to	Nicotine	
Replacement	Therapy	(Nicotine	Patch)	Among	Homeless	Persons	Enrolled	in	a	Randomized	Controlled	Trial	
Targeting	Smoking	Cessation.	Journal	of	family	medicine.	2016;3(7):1079	
13	Tsang	IK,	Tsoh	JY,	Wong	C,	et	al.	Understanding	and	use	of	nicotine	replacement	therapy	and	nonpharmacologic	
smoking	cessation	strategies	among	Chinese	and	Vietnamese	smokers	and	their	families.	Prev	Chronic	Dis	
2014;11:E26.	doi:	10.5888/pcd11.130299	
14	Burns	EK,	Levinson	AH.	Discontinuation	of	nicotine	replacement	therapy	among	smoking-cessation	attempters.	
Am	J	Prev	Med	2008;34(3):212-5.	doi:	10.1016/j.amepre.2007.11.010	
15	Kotz	D,	Brown	J,	West	R.	Prospective	cohort	study	of	the	effectiveness	of	smoking	cessation	treatments	used	in	
the	“real	world.”	Mayo	Clin	Proc.	2014;89(10):1360–1367.			
Kotz	D,	Brown	J,	West	R.	“Real-world”	effectiveness	of	smoking	cessation	treatments:	a	population	study.	
Addiction.	2014;109(3):491–499.			
Leas,	EC,	et	al,	Effectiveness	of	Pharmaceutical	Smoking	Cessation	Aids	in	a	Nationally	Representative	Cohort	of	
American	Smokers.		JNCI:	Journal	of	the	National	Cancer	Institute,	djx240,	https://doi.org/10.1093/jnci/djx240.		
Published:	21	December	2017.	
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2. Are there additional indications or regimens for OTC NRT products that could be 
explored? Concepts to consider could include relapse prevention, craving reduction, 
maintenance, reduce to quit, use of short- and long-acting products in combination, 
or cessation of non-cigarette tobacco products. What evidence would be needed to 
support each indication or regimen? 
 
For the reasons discussed throughout the rest of this comment, using OTC NRT without 
evidence-based smoking cessation support and without an endpoint as complete abstinence from 
any form of tobacco products, is unlikely to produce health benefits and should not be 
recommended. 
 
3. What data would be required to demonstrate health benefits of reduction in 
consumption of combustible tobacco products? 
 
Foremost, no level of combustible tobacco use is safe, and reduction should not be the 
goal or an acceptable outcome of any treatment regimen.  
 
The risk of cardiovascular diseases, which kill more smokers than cancer or respiratory 
diseases combined each year,16 is almost as high among low consumption or infrequent smokers 
compared to high consumption smokers. In 2012, an estimated 85.6 million U.S. adults (35%) 
had at least one cardiovascular disease17 and in 2013, cardiovascular diseases accounted for 
roughly 1 in 3 (30.8%) U.S. deaths (800,937 of 2,596,993 deaths).18 Of the five major risk 
factors for cardiovascular diseases (hypertension, smoking, poor diet, insufficient physical 
activity, and abnormal glucose levels) smoking is the second in terms of contribution to 
cardiovascular disease incidence in the U.S.19 Given the steep dose-response relationship 
between smoking and cardiovascular disease risk, the high prevalence of cardiovascular diseases 
in the U.S., and the fact that most smokers actually die from cardiovascular diseases and not 
from cancer or respiratory diseases, FDA should not encourage reduction as a goal or 
acceptable outcome of a treatment regimen.  
 
In theory there may be some reduction in risk of some other disease outcomes for 
individuals who significantly reduce their smoking consumption. However, because to date there 
has been no scientific evidence supporting this theory, both short and long-term rigorous 
studies will be required to demonstrate potential benefits of reduction before the FDA 
advocates this as a public health strategy. 
 
Short-term studies can compare biomarkers of exposure and effect during regular 
consumption and reduced consumption. The most robust study design would be within-subject 
                                                
16	Mozaffarian	D,	Benjamin	EJ,	Go	AS,	Arnett	DK,	Blaha	MJ,	Cushman	M,	et	al.	Heart	disease	and	stroke	statistics—
2016	update.	Circulation.	2016;133(4):e38-e360.	
17	Mozaffarian	D,	Benjamin	EJ,	Go	AS,	Arnett	DK,	Blaha	MJ,	Cushman	M,	et	al.	Heart	disease	and	stroke	statistics—
2016	update.	Circulation.	2016;133(4):e38-e360.	
18	National	Center	for	Health	Statistics.	Mortality	multiple	cause	micro-data	files,	2013:	public-use	data	file	and	
documentation:	NHLBI	tabulations.	2014.	
19	Mozaffarian	D,	Benjamin	EJ,	Go	AS,	Arnett	DK,	Blaha	MJ,	Cushman	M,	et	al.	Heart	disease	and	stroke	statistics—
2016	update.	Circulation.	2016;133(4):e38-e360.	
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comparisons, such as crossover studies, or randomized controlled trials. The studies should be of 
sufficient duration to allow characterization of biomarkers of longer term tobacco smoke 
exposure and not just recent use (as in a few days). An appropriate biomarker of exposure is the 
tobacco-specific nitrosamine, NNAL. NNAL is a biomarker of exposure to NNK, both of which 
are potent pulmonary carcinogens.20 NNAL has a half-life of about 2 weeks and would be ideal 
to assess smoking patterns over several weeks to months. Reduction in NNAL would indicate 
reduction in exposure to tobacco smoke (and not just reduction in number of cigarettes smoked 
since people can smoke fewer cigarettes but compensate by smoking each cigarette more 
intensely). Short-term studies should also characterize changes in biomarkers of 
pathophysiological mechanisms that are associated with increased risk of diseases. Oxidative 
stress, for example, underlies many diseases, including cardiopulmonary diseases and cancer. 
Thus, biomarkers of oxidative stress should be measured. Other endpoints include markers of 
respiratory injury, DNA adducts (to assess cancer risk), and intermediate physiological outcomes 
that may indicate increased disease risk such as heart rate and blood pressure changes, lung 
function, and measures of endothelial function, such as flow mediated dilation (FMD). Favorable 
changes in biomarkers of exposure to tobacco smoke and various biomarkers of effect would 
indicate reduced risk of diseases from reduction.  
 
Long-term studies can include observational studies to examine risk of tobacco-related 
diseases among smokers who reduce consumption and those who do not. These studies would 
require large sample sizes. Longitudinal cohort studies would be ideal but these studies are 
expensive and given the latency between tobacco use and clinical endpoints, they would be more 
difficult to carry. Case-control studies, although retrospective, would be more practical. Cross-
sectional studies to assess prevalence of diseases, symptoms, levels of biomarkers of effects and 
exposure among people who reduce consumption and those who do not can also provide useful 
information on potential benefits of reduction. However, cross-sectional studies are limited in 
that they do not include a temporal component. 
 
In summary, it is unlikely that smoking reduction would result in decreased 
cardiovascular disease risk, the disease that kills most smokers. For that reason, reduction 
should not be a goal in smoking treatment.  
 
 
4. Are there OTC NRT products that could be studied for use in combination that 
might result in reduced tobacco-related health impacts? What evidence would be 
needed to support the safety and efficacy of these products when used in 
combination? 
 
Before considering which NRT products could be used in combination and how they 
should be used to increase safety and efficacy, FDA must first consider whether using OTC 
NRT products in combination may result in an increased likelihood of dual or concurrent use 
of various tobacco products, and the potential tobacco-related health impacts resulting from 
such use.  Emerging scientific evidence shows significant increased health risks associated with 
dual use of tobacco products, and a recent analysis of population-based data showed that current 
adult cigarette smokers in the U.S. who report using e-cigarettes had greater disease symptoms 
                                                
20	Hecht	SS.	Tobacco	smoke	carcinogens	and	lung	cancer.	J	Natl	Cancer	Inst.	1999;91(14):1194-210.	
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such as chest pains, ulcers or sores in the month, cold or wheezing.21  Thus, the potential 
increased harm that may result from a combination of nicotine/tobacco products use should be 
given serious consideration.   
 
A meta-analysis of all available studies (published through February 14, 2018) examining 
the relationship between e-cigarette use and smoking cessation shows that, in the real world, for 
most smokers’ e-cigarette use substantially reduces the odds of smoking cessation.22 
 
FDA’s proposal to use so-called “innovative technologies” such as e-cigarettes or 
heated tobacco products is therefore not a good strategy to tackle nicotine regulation or 
addiction because of its likelihood to increase dual or concurrent use of tobacco products, 
including cigarettes, cigars, and hookah, and its likelihood to attract youth and adolescents to 
initiate tobacco use.  
 
5. Is there other information that could be added to labeling for currently approved or 
new dosage forms of OTC NRT products that would maximize their ability to be 
used to support smoking cessation? Please consider the various sections of the Drug 
Facts labeling, including the Uses, Warnings, and Directions sections. 
 
It is important to note that while NRT is a proven cessation intervention when combined 
with counselling, the evidence consistently shows that NRT used without counselling is 
ineffective – or even harmful – in terms of promoting cessation.23  Many states and medical 
systems provide NRT alone; this practice should be discouraged as a wasteful – and possibly 
counterproductive – use of resources.  OTC NRT labeling should clearly direct NRT users to 
obtain smoking cessation support from health professionals and/or a smoking cessation 
counseling program because unsupported OTC NRT may make it harder to quit.  Additionally, 
labeling should include warnings about the potential harms of improperly using NRT together 
with other forms of tobacco products unless directed or monitored by a health professional or a 
smoking cessation counseling program with the end-goal of achieving smoking cessation. 
This issue is of particular concern because the tobacco industry is now entering the 
NRT business as part of a plan to retain customers, informed by their understanding that NRT 
use without counselling likely depresses cessation.   
                                                
21	Yao	T,	Max	W,	Sung	HY,	Glantz	SA,	Goldberg	RL,	Wang	JB,	Wang	Y,	Lightwood	J,	Cataldo	J.	Relationship	between	
spending	on	electronic	cigarettes,	30-day	use,	and	disease	symptoms	among	current	adult	cigarette	smokers	in	the	
U.S.	PLoS	ONE.	2017;12(11):e0187399.	Epub	2017/11/08.	doi:	10.1371/journal.pone.0187399.	PubMed	PMID:	
29112988;	PubMed	Central	PMCID:	PMCPMC5675454.	
22	Glantz	S,	Bareham	D.		E-Cigarettes:	Use,	Effects	on	Smoking,	Risks,	and	Policy	Implications.		Annual	Review	of	
Public	Health	2018	39:1		http://www.annualreviews.org/doi/10.1146/annurev-publhealth-040617-013757	
23		Kotz	D,	Brown	J,	West	R.	Prospective	cohort	study	of	the	effectiveness	of	smoking	cessation	treatments	used	in	
the	“real	world.”	Mayo	Clin	Proc.	2014;89(10):1360–1367.			
Kotz	D,	Brown	J,	West	R.	“Real-world”	effectiveness	of	smoking	cessation	treatments:	a	population	study.	
Addiction.	2014;109(3):491–499.			
Leas,	EC,	et	al,	Effectiveness	of	Pharmaceutical	Smoking	Cessation	Aids	in	a	Nationally	Representative	Cohort	of	
American	Smokers.		JNCI:	Journal	of	the	National	Cancer	Institute,	djx240,	https://doi.org/10.1093/jnci/djx240.		
Published:	21	December	2017.	
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The following cartoon illustration, “The Smoker’s Timeline” depicts the danger of 
encouraging NRT use without provision of cessation counseling support. 
 
As Apollonio and Glantz24 noted: 
Major tobacco companies in the United States and the United Kingdom viewed 
NRT, even when it was only available by prescription, as a recreational product 
that could maintain and possibly expand the use of nicotine as smoking became 
less socially acceptable. Although NRT was approved for cessation, tobacco 
industry research found in the early 1990s that many smokers used it in 
combination with cigarettes and that smokers who used NRT for cessation would 
otherwise have quit outright. 49–51,53,54 
In the 21st century, medical research began to find similar results. The majority of 
smokers who receive prescription NRT receive counseling on how to use the 
medication.59 Initial clinical trials suggesting comparable effectiveness for OTC 
NRT relied on simulated OTC use rather than real-world OTC use.11–16 Follow-up 
population studies of OTC NRT showed it did not improve—and could impede—
cessation, without an organized cessation program.8,9,17,18 Outside of monitored 
settings, NRT is often used for shorter periods than recommended and not 
combined with behavioral counseling.10 These findings are consistent even among 
individuals motivated to quit: a follow-up study of participants enrolled in a 
clinical trial of nicotine patch users found that after 8 years, there was no 
                                                
24	Apollonio	D,	Glantz	SA.		Tobacco	Industry	Research	on	Nicotine	Replacement	Therapy:	"If	Anyone	Is	Going	to	
Take	Away	Our	Business	It	Should	Be	Us".		Am	J	Public	Health.	2017	Oct;107(10):1636-1642.	doi:	
10.2105/AJPH.2017.303935.	Epub	2017	Aug	17.	
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statistically significant difference in abstinence for patch users than nonusers.60 
Moreover, smokers who used over-the-counter NRT were significantly less likely 
to quit than were smokers who did not use any cessation aids.8,9 
Tobacco companies expressed interest in developing and marketing alternative 
products containing nicotine as early as the 1950s, but they were concerned about 
marketing them because doing so could lead to FDA regulation. In 2009, 
following new FDA regulation of cigarettes, tobacco companies began selling the 
alternative nicotine products they had first proposed decades earlier.61 In 2014, RJ 
Reynolds Tobacco began selling its nicotine gum, Zonnic, throughout the United 
States. Internally, RJR classified Zonnic with its e-cigarette brand Vuse, 
considering both products to be part of its “quest toward becoming a ‘total 
tobacco company.’”4 Reflecting this ambition, marketing in 2015 for Zonnic 
suggested that smokers could use it with cigarettes: “Quitting doesn’t have to feel 
like all or nothing.”61 This marketing is consistent with tobacco industry research 
that found many smokers used NRT in combination with cigarettes instead of as a 
means to quit smoking. Philip Morris began marketing nicotine lozenges in 
2016.5,6   
… 
Tobacco industry research from the 1970s forward treated all products containing 
nicotine—including cigarettes, e-cigarettes and their precursors, and others (e.g., 
gums, patches, and candy)—as part of a single market: the nicotine delivery, or 
Craving Relief market. Industry marketing anticipates that noncigarette nicotine 
delivery products will be used by smokers for whom smoking is unacceptable, 
thus facilitating and normalizing lifelong nicotine addiction. These findings 
suggest that the least harmful way to sell nicotine delivery products is to restrict 
them to smokers whose quit attempts are medically supervised, consistent with 
the original studies of NRT for smoking cessation.7  
[Citations in this excerpt are found in: Apollonio D, Glantz SA.  Tobacco Industry 
Research on Nicotine Replacement Therapy: "If Anyone Is Going to Take Away 
Our Business It Should Be Us".  Am J Public Health. 2017 Oct;107(10):1636-
1642. doi: 10.2105/AJPH.2017.303935. Epub 2017 Aug 17.] 
These findings provide further evidence that FDA should not support the tobacco 
industry’s playbook by including e-cigarettes and other supposedly “innovative technologies” 
as part of its nicotine reduction strategy.  Indeed, such a strategy is more likely to facilitate or 
normalize addiction to nicotine, especially among youth, rather than reduce nicotine 
addiction.   
In conclusion, the following information should be clearly provided in the Uses, 
Directions, and Warnings sections of the Drug Facts labeling on any OTC NRT products:  
 
  9 
(1) Uses:  
 
The use of these products should be limited to smoking cessation. While smoking 
cessation for some individuals may involve gradual reduction of 
cigarettes/tobacco product consumption, the ultimate goal of using these products 
should be directed toward complete smoking abstinence. 
 
(2) Directions:  
 
The use of NRT should be integrated with concurrent use/participation in a 
smoking cessation program* to increase likelihood of achieving smoking 
abstinence.   
 
In addition, the combined use of faster-acting NRT medications with nicotine 
patch, or use of NRT prior to quit date or for smoking reduction should be guided 
by a health professional or a smoking cessation program as part of a quit attempt 
with an endpoint as achieving complete smoking abstinence from cigarettes 
and/or other forms of tobacco products.   
 
(3) Warnings:   
 
Use of NRT products without smoking cessation counseling support or 
consultation with a health provider may decrease the likelihood of quitting 
smoking.  
* Examples of evidence-based accessable free resources of smoking cessation programs 
include the Quitline and smokefree.gov resources, advice from healthcare providers, smoking 
cessation classes that use evidence-based curriculum from trusted authority such as the 
American Lung Association, American Heart Association, American Cancer Society, and the 
National Institutes of Health / National Cancer Institute. 
 
6. Generally, the labeling of OTC NRT products contains a dosing schedule based on 
duration of use, and FDA has recommended the labeling on OTC NRT products be 
modified to include the following: “If you feel you need to use [the NRT product] for 
a longer period to keep from smoking, talk to your health care provider.” What is 
the impact of longer term NRT treatment? What is the impact on likelihood of 
cessation or relapse prevention? What data would support an affirmative 
recommendation to use approved OTC NRT products for durations that exceed 
those currently included in the Drug Facts labeling of approved OTC NRT 
products, or would support a chronic or maintenance drug treatment indication for 
such products? 
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Scientific evidence has not demonstrated extended NRT use (beyond 12 weeks of 
recommendation) and smoking abstinence.25  However, extended cognitive behavioral smoking 
cessation treatments, with or without availability of NRT, have produced unparalleled long-term 
abstinence rates from 45% to 55% abstinence rates at 1 year or beyond.26, 27  Mobile 
interventions may be an ideal medium to provide extended treatments or smoking cessation 
support. In 2017, the Pew Research Center reported that 95% of Americans own a cellphone28 
and 70% use social media.29  Given mobile interventions for tobacco use have a broad reach, 
extended treatment or support can be implemented after an intensive face-to-face intervention, or 
in a form of electronic contacts with tailored and extensive contents, or to provide support for 
extended prescription to yield high abstinence rates.30   
 
While extended use of NRT has not been linked to safety concerns, it is essential for 
FDA to inform the public regarding the importance of receiving smoking cessation counseling 
support with NRT use in order to achieve long-term smoking abstinence. Importantly, the 
evidence consistently shows that NRT used without counselling is ineffective  –  or even 
harmful  –  in terms of promoting cessation.31   Any provision of extended NRT treatment 
should be accompanied by evidence-based smoking cessation support. 
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In summary, FDA’s approach to NRT must be based on the following evidence-
based points: 
(1) there is no safe level of combustible tobacco use; 
(2) smoking reduction should not be the goal or an acceptable outcome of any NRT 
treatment regimen; 
(3) complete cigarette cessation and complete abstinence from any alternative tobacco 
products should be the desired endpoint; 
(4) NRT used without counselling is ineffective, or even harmful, in terms of promoting 
cessation; 
(5) OTC NRT effectiveness requires direct efforts to improve adherence; 
(6) Combined use of NRT, especially with e-cigarettes and other so-called “innovative 
technologies,” is likely to be associated with dual use with other tobacco products and 
is more likely to facilitate nicotine addiction, rather than reduce addiction; and 
(7) NRT labeling should include clear directions and warnings to direct users to use NRT 
with smoking cessation support and to use NRT with the end-goal of complete 
abstinence of any tobacco products.   
